Alternative Outpatient Chemotherapy Scheduling Method to Improve Patient Service Quality and Nurse Satisfaction.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

New guidelines from the NCCN for polycythemia vera.

The use and impact of Twitter at medical conferences: Best practices and Twitter etiquette.

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

Approach to MPN Symptom Assessment.

A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.